glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
== Television presenter == In an overview of the broadcasting organisations Galloway works for, Tom Rogan in the National Review in April 2014 described him as being "a Western puppet for tyranny's propagandists". In August 2009, editions of Galloway's programmes The Real Deal and Comment programme for Press TV, a London-based news channel controlled by the government of Iran, were found by the British broadcasting regulator Ofcom to have breached its broadcasting code on impartiality. After Press TV lost its Ofcom licence in 2012, according to Galloway, the Iranian broadcaster owed him £40,000, leading to his company Miranda Media entering compulsory liquidation in 2013 because of unpaid tax. Reportedly, the owed payment amounts to £100,000, although Galloway disputed this in February 2016. Miranda Media, in which income from Galloway's media work was deposited, was established in September 2007 under a month before a law came into force allowing directors to receive loans from their own companies, a facility Galloway used on multiple occasions. Shortly after its foundation in June 2012, Galloway became a presenter with the Al Mayadeen television station where he presents "Kalima Hurra" (Arabic: كلمة حرّة meaning free word). Al Mayadeen reportedly has connections with Iran and the Assad government in Syria, and has been accused of supporting the Assad government, a claim Galloway has rejected. In November 2013, Galloway and his wife Gayatri began to present Sputnik for the Russian government-backed station RT. He is a regular contributor to RT's other programming.
=== Anti-corruption campaigns === Bukele established the International Commission Against Impunity in El Salvador (CICIES) in September 2019, an anti-corruption commission to combat drug trafficking, corruption, and white-collar crimes. CICIES was operated by the Salvadoran government and the Organization of American States (OAS), and cooperated with the National Civil Police to form an anti-corruption unit. Bukele dissolved CICIES in June 2021 after the OAS named Ernesto Muyshondt an anti-corruption advisor; Ernesto Muyshondt was accused by the Salvadoran government of electoral fraud and illegal negotiation with gang members to vote for ARENA during the 2014 presidential election. He was arrested and was scheduled to go on trial in April 2024, despite concerns about his health. On 1 June 2023, during a speech celebrating his fourth year in office, Bukele stated that his government would begin a "war against corruption" ("guerra contra la corrupción"). He announced that he would build a prison for individuals convicted of white-collar crimes that would be similar to the Terrorism Confinement Center. Bukele stated that the police and military would arrest white-collar criminals like they capture gang members in the gang crackdown. He added that Attorney General Rodolfo Delgado was in the process of raiding and confiscating assets worth up to $68 million from former Salvadoran president Alfredo Cristiani as part of the anti-corruption campaign.
=== Russell === Russell (voiced by Rhys Darby) is Alyx's scientist ally and over-the-radio companion. Russell tried to get a job at Black Mesa, never getting the chance when the Black Mesa Incident happened. Before the Combine takeover of Earth, Russell either downloaded all of or a majority of the internet, providing information to the Resistance.
=== Chemistry of hydrogen exchange === One of the major complications in studying hydrogen isotopes is the issue of exchangeability. At many time scales, ranging from hours to geological epochs, scientists have to consider if the hydrogen moieties in studied molecules are the original species or if they represent exchange with water or mineral hydrogen near by. Research in this area is still inconclusive in regards to rates of exchange, but it is generally understood that hydrogen exchange complicates the preservation of information in isotope studies.
Sources: en.wikipedia.org
During the final years of the 20th century, Gaddafi—frustrated by the failure of his pan-Arab ideals and the refusal of the Arab world to challenge the international air embargo imposed on Libya—increasingly rejected Arab nationalism in favour of pan-Africanism, emphasizing Libya's African identity. In a 1998 interview, Gaddafi claimed that "the Arab world is finished" and expressed his wish for Libya to become a "black country". From 1997 to 2000, Libya initiated cooperative agreements or bilateral aid arrangements with 10 African states, and in 1999 joined the Community of Sahel–Saharan States (CEN–SAD). In June 1999, Gaddafi visited Mandela in South Africa, and the next month attended the OAU summit in Algiers, calling for greater political and economic integration across the continent and advocating the foundation of a United States of Africa. He became one of the founders of the African Union (AU), initiated in July 2002 to replace the OAU. At the opening ceremonies, he called for African states to reject conditional aid from the developed world, a direct contrast to the message of South African President Thabo Mbeki. There was speculation that Gaddafi wanted to become the AU's first chair, raising concerns within Africa that this would damage the Union's international standing, particularly with the West.
=== Amphibian === The unfertilized oocyte of a frog, or Xenopus laevis, has also been utilized as an expression system for heterologous expression. Initially used to express the acetylcholine receptor in 1982, since then it has been used for a variety of reasons. These oocytes are produced by frogs year round and thus are relatively abundant, and translation occurs with high fidelity. Of the many limitations to the oocyte system, one major one is that the produced heterologous proteins interact with the frog oocyte's proteins which changes its behavior compared to what it would be in a mammalian cell. Additionally, where mammals are diploid, these xenopus have four homologous copies of each chromosome and thus, proteins derived may have a different function. More research is needed to examine the protein production of X. laevis systems.
After two years, the inquiry concluded with three principal findings and several recommendations, including required training for administrators, directors of nursing, and service organizations, improved screening processes and background checks for new hires, minimizing the use of agency nurses in long-term care homes, improved reporting processes for critical incidents, and changes to certain Ontario provincial regulations.
=== EC 1.99.2 Oxygenases (now covered by EC 1.13) === EC 1.99.2.1: deleted, now EC 1.13.11.12, lipoxygenase EC 1.99.2.2: deleted, now EC 1.13.11.1, catechol 1,2-dioxygenase EC 1.99.2.3: deleted, now EC 1.13.11.3, protocatechuate 3,4-dioxygenase EC 1.99.2.4: deleted, now EC 1.13.11.4, gentisate 1,2-dioxygenase EC 1.99.2.5: deleted, now EC 1.13.11.5, homogentisate 1,2-dioxygenase EC 1.99.2.6: deleted, now EC 1.13.99.1, inositol oxygenase
In 2002, Applied Biosystems reached revenues of US$1.6 billion for the year, and took control from Celera of the support of Celera Discovery System (CDS), a data tool to answer specific genomic and proteomic queries, involving the new genetic data field of tens of thousands of single-nucleotide polymorphisms (SNPs) within the human genome. The company developed another new tool, which combined the first ever union of triple quadrupole and ion trap technologies, in proteomics research. The database itself would remain with Celera, because of shareholder approval complications. Celera would retain responsibility for its maintenance and support to existing customers, and would receive royalties from Applied Biosystems. In 2003, Catherine Burzik joined Applied's management, from Ortho-Clinical Diagnostics. Applied developed a new tool which measured antibody/antigen binding in real-time kinetic analysis of up to 400 binding interactions simultaneously. In 2004, Mike Hunkapiller retired and Cathy Burzik replaced him as President of Applied Biosystems. Applera collaborated with General Electric, Abbott Laboratories, Seattle Genetics, and Merck in diagnostics development. Applied Biosystmes also teamed with Northrop Grumman and Cepheid of Sunnyvale, California, to detect Bacillus anthracis during the anthrax contamination case of the U.S. Postal Service. In 2005, the company released new tools for small molecule quantitation in pharmaceutical drug development.
Sources: en.wikipedia.org
== Use and toxicity == The European species did not enter into the herbalists' pharmacopeia. In the American Old West, the Western white clematis, Clematis ligusticifolia, was called pepper vine by early travelers and pioneers, who took a tip from Spanish colonials and used seeds and the acrid leaves of yerba de chivato as a pepper substitute. The entire genus contains essential oils and compounds which are extremely irritating to the skin and mucous membranes. Unlike black pepper or Capsicum, however, the compounds in clematis cause internal bleeding of the digestive tract if ingested in large amounts. C. ligusticifolia is essentially toxic. When pruning them, it is a good idea to wear gloves. Despite its toxicity, Native Americans used very small amounts of clematis as an effective treatment for migraine headaches and nervous disorders. It was also used as an effective treatment of skin infections. Clematis is also a constituent of Bach's Rescue Remedy. Leaf extracts from two Ethiopian species (Clematis longicauda steud ex A. Rich. and Clematis burgensis Engl.) are used locally to treat ear disorders and eczema. Phytochemical screening of the extracts from both of these species showed antibacterial and antifungal activity. The extracts of these plants also possess wound healing and anti-inflammatory activities which could also be attributed to the phytoconstituents. Clematis has been listed as one of the 38 plants used to prepare Bach flower remedies, a kind of alternative medicine promoted for its effect on health.
== Clinical significance == It was hoped that ANGPTL8 or its homolog in humans may provide an effective treatment for type 2 diabetes and perhaps even type I diabetes. Unfortunately, since new data have greatly called into question the ability of ANGPTL8 to increase beta-cell replication, its potential use as a therapy for type 2 diabetes is limited. Inhibition of ANGPTL8 represents a possible therapeutic strategy for hypertriglyceridemia. In a clinical trial, a human ANGPTL3/8 monoclonal antibody reduced the concentration of triglycerides (-70%), and low-density lipoprotein cholesterol (-32%), while increasing HDL- cholesterol (+27%), representing a promising therapy for multiple lipid disorders.
During character creation, each upgrade costs one point. The upgrade cost increases as the game progresses. Each ability can be raised from zero to five, and it is impossible to accrue enough experience points to complete every skill (allowing the player to specialize or balance their character). Experience points are gained by completing quests, finding items, or unlocking secret paths rather than killing enemies and are used to increase or unlock the character's statistics and abilities. The game features a main story and optional side quests that can be completed at any time; the player can move between the available areas at will to revisit locations, characters, or merchants. The player's clan affects their skills and powers. Although the attractive Toreadors receive bonuses for seduction and persuasion, opening additional dialogue options, they are physically weak; the Nosferatu are forced to travel in the shadows or through sewers to avoid alerting humans but receive bonuses to their intelligence and computer skills, which enables access to more information. The Malkavians have different dialogue options, reflecting their inherent insanity. Upgrading some skills provides additional dialogue options; attractive and charismatic characters seduce to get their way, aggressive characters threaten, and others persuade their targets to cooperate.
==== Bipolar disorder ==== Pioglitazone has been repurposed as an add-on treatment for depressive episodes in subjects with bipolar disorder. However, meta-analytic evidence is based on very few studies and does not suggest any efficacy of pioglitazone in the treatment of bipolar depression.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.